Breaking News Instant updates and real-time market news.

ONTX

Onconova

$3.47

-0.29 (-7.71%)

07:32
12/10/18
12/10
07:32
12/10/18
07:32

Onconova names Avi Oler as VP, corporate development and general counsel

Onconova Therapeutics (ONTX) announced that Abraham "Avi" Oler has joined Onconova's management team as Vice President, Corporate Development and General Counsel. Oler will be primarily responsible for business development, investor relations, and legal affairs of the company. To help further advance Rigosertib, the company's Phase 3 candidate for MDS, Oler's focus will be on forging new collaborations in additional geographies. Rigosertib is currently partnered with SymBio Pharmaceuticals for Japan and Korea, and with Pint Pharma for Latin America. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals (SPPI).

ONTX Onconova
$3.47

-0.29 (-7.71%)

12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.
10/11/18
MAXM
10/11/18
NO CHANGE
Target $16
MAXM
Buy
Onconova price target lowered to $16 at Maxim to reflect reverse stock split
Maxim analyst Jason MacCarthy lowered his price target on Onconova to $16 from $45 to reflect the impact of the company's 1-for-15 reverse stock split announced on September 25th which reduced the number of shares outstanding to 5.67M from 85.11M. McCarthy also keeps his Buy rating on the shares and notes that his bullish stance remains intact as the company's "rigosertib phase 3 program continues to enroll and timelines remain unchanged".
05/03/18
MAXM
05/03/18
UPGRADE
Target $3
MAXM
Buy
Onconova upgraded to Buy at Maxim on renewed Rigosertib investor focus
As reported earlier, Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold with a price target of $3. The analyst notes that investors' focus is shifting to Rigosertib now that the company's "financing roadblock has been cleared". McCarthy believes that "Rigosertib could emerge as the first targeted therapy approved for MDS based on the mechanism of action and both prior and emerging data".
05/02/18
MAXM
05/02/18
UPGRADE
MAXM
Buy
Onconova upgraded to Buy from Hold at Maxim

TODAY'S FREE FLY STORIES

DLTR

Dollar Tree

$108.85

0.445 (0.41%)

11:21
11/14/19
11/14
11:21
11/14/19
11:21
Hot Stocks
FDA sends warning letter to Dollar Tree regarding violations at drug suppliers »

In an FDA warning letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/14/19
11/14
11:17
11/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/14/19
11/14
11:16
11/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Powell on changing policy: »

Powell on changing…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BA

Boeing

$362.00

-0.42 (-0.12%)

11:14
11/14/19
11/14
11:14
11/14/19
11:14
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing moves to session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement CUSIP Number data reported »

10-Yr TIPS Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement Offering Amount data reported »

10-Yr TIPS Announcement…

11:10
11/14/19
11/14
11:10
11/14/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

11:07
11/14/19
11/14
11:07
11/14/19
11:07
Hot Stocks
BioMarin sees GAAP break-even or better in 2020 assuming Valoctocogene launch »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

GILD

Gilead

$62.48

-0.85 (-1.34%)

11:05
11/14/19
11/14
11:05
11/14/19
11:05
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:05
11/14/19
11/14
11:05
11/14/19
11:05
General news
Powell:the day of reckoning could be "quite far off," »

Powell:the day of…

USO

United States Oil Fund

$12.05

0.09 (0.75%)

11:00
11/14/19
11/14
11:00
11/14/19
11:00
General news
Crude inventories for week of November 8 »

Crude oil inventories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$263.91

-0.61 (-0.23%)

10:58
11/14/19
11/14
10:58
11/14/19
10:58
On The Fly
Maxim says sell Apple on concern about 2020 iPhone sales »

Maxim analyst Nehal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$237.81

0.17 (0.07%)

10:56
11/14/19
11/14
10:56
11/14/19
10:56
Periodicals
Breaking Periodicals news story on Air Products »

Lombard Odier's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
11/14/19
11/14
10:55
11/14/19
10:55
General news
Powell: the U.S. is the star economy »

Powell: the U.S. is the…

OPTT

Ocean Power

$1.49

-0.005 (-0.33%)

10:55
11/14/19
11/14
10:55
11/14/19
10:55
Conference/Events
Ocean Power to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

AAPL

Apple

$263.82

-0.7 (-0.26%)

, UBER

Uber

$25.97

-0.73 (-2.73%)

10:53
11/14/19
11/14
10:53
11/14/19
10:53
On The Fly
Apple downgrade, Uber upgrade among today's top analyst calls »

Check out today's top…

AAPL

Apple

$263.82

-0.7 (-0.26%)

UBER

Uber

$25.97

-0.73 (-2.73%)

KHC

Kraft Heinz

$31.79

-1.1 (-3.34%)

VZ

Verizon

$59.16

-0.25 (-0.42%)

T

AT&T

$38.93

-0.22 (-0.56%)

TMUS

T-Mobile

$77.04

-0.98 (-1.26%)

ATUS

Altice USA

$26.91

0.07 (0.26%)

BYND

Beyond Meat

$81.24

2.26 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

10:50
11/14/19
11/14
10:50
11/14/19
10:50
General news
More Powell: the long expansions have been a function of getting inflation under control »

More Powell: the long…

VTGN

VistaGen Therapeutics

$0.34

-0.7449 (-68.65%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Downgrade
VistaGen Therapeutics rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$191.00

0.84 (0.44%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Options
Cigna call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 22

    Nov

  • 09

    Dec

  • 06

    Feb

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY hit…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.